0001562180-21-003468.txt : 20210513
0001562180-21-003468.hdr.sgml : 20210513
20210513204521
ACCESSION NUMBER: 0001562180-21-003468
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210511
FILED AS OF DATE: 20210513
DATE AS OF CHANGE: 20210513
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sama Rinda
CENTRAL INDEX KEY: 0001756399
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38721
FILM NUMBER: 21921585
MAIL ADDRESS:
STREET 1: 26 TECHNOLOGY DRIVE
CITY: IRVINE
STATE: CA
ZIP: 92618
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axonics, Inc.
CENTRAL INDEX KEY: 0001603756
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 454744083
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 TECHNOLOGY DRIVE
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: 949-396-6322
MAIL ADDRESS:
STREET 1: 26 TECHNOLOGY DRIVE
CITY: IRVINE
STATE: CA
ZIP: 92618
FORMER COMPANY:
FORMER CONFORMED NAME: Axonics Modulation Technologies, Inc.
DATE OF NAME CHANGE: 20140326
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2021-05-11
false
0001603756
Axonics, Inc.
AXNX
0001756399
Sama Rinda
26 TECHNOLOGY DRIVE
IRVINE
CA
92618
false
true
false
false
Chief Operating Officer
Common Stock
2021-05-11
4
M
false
2622.00
1.63
A
41917.00
D
Common Stock
2021-05-11
4
M
false
3681.00
14.19
A
45598.00
D
Common Stock
2021-05-11
4
M
false
8300.00
25.82
A
53898.00
D
Common Stock
2021-05-11
4
S
false
20162.00
53.0917
D
33736.00
D
Common Stock
2021-05-11
4
S
false
4838.00
54.4039
D
28898.00
D
Common Stock
4000.00
I
By Spouse
Stock Option (Right to Buy)
1.63
2021-05-11
4
M
false
2622.00
0.00
D
2028-03-30
Common Stock
2622.00
6294.00
D
Stock Option (Right to Buy)
14.19
2021-05-11
4
M
false
3681.00
0.00
D
2029-01-30
Common Stock
3681.00
41568.00
D
Stock Option (Right to Buy)
25.82
2021-05-11
4
M
false
8300.00
0.00
D
2029-12-12
Common Stock
8300.00
18263.00
D
The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $52.80 to $53.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $53.82 to $54.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on March 30, 2018, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of March 30, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.
The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on January 30th, 2020, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of January 30th, 2020, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.
The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on December 12, 2020, and the remainder vesting at a rate of 1/36th per month thereafter, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer.
/s/ Dan Dearen, as Attorney-in-Fact for Rinda Sama
2021-05-13